The European Medicines Agency could this week decide whether to reverse the opinion it adopted in February recommending against pan-EU marketing approval for MSD/Ridgeback Biotherapeutics’ COVID-19 treatment, Lagevrio (molnupiravir).
Key Takeaways
- The latest monthly meeting of the European Medicines Agency’s human medicines committee, the CHMP, is taking place on 19-22 June.
- New drugs listed on the meeting's draft agenda as being up for an opinion by the CHMP on whether they should be granted pan-EU marketing approval include Amylyx Pharmaceuticals’ sodium phenylbutyrate/ursodoxicoltaurine, AbbVie’s atogepant, GSK’s daprodustat and the generic or hybrid drug enalapril maleate.
- A decision on whether the EMA will overturn its rejection of MSD/Ridgeback Biotherapeutics’ COVID-19 treatment, Lagevrio, is also expected
MSD was today due to present at an oral explanation meeting before the EMA’s human medicines committee, the CHMP, to make its case for approving the drug, according to the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?